Skip to main content

Lewis J. Geffen

Member Emeritus

Share:

Lewis retired from Mintz in 2025. He was previously a Member in the firm's Corporate Practice.

viewpoints

Despite choppy market conditions for private companies, the Mintz Venture Capital & Emerging Companies team remained busy advising emerging companies of all sizes and at all stages of growth across a wide range of industries. For the first half of 2023 we completed 72 transactions, with an aggregate deal value in excess of $1.6 billion. Below are a few highlighted transactions:

Read more

This edition of Mintz Venture Watch reports on the firm’s VC transaction activity in 2022, including data for Q3 and Q4. Mintz represented issuers and investors in the life sciences, cybersecurity, energy, and other sectors in more than 128 transactions valued at more than $3 billion in 2022.  

Read more
Venture capital investing continues to thrive across all sectors. During the first half of 2021, the Mintz team advised more than 65 emerging companies and investors in transactions in all facets of the life sciences, technology, and energy and sustainability industries.
Read more
This 90-minute webinar explored the processes, considerations, and other factors behind the incubation and launch of new companies by some of today’s leading venture capital firms. Panelists discussed common sources of ideas for new companies, de-risking of translational science, ideal initial management, and financing a new entity.
Read more
Section 141(d) of the Delaware General Corporations Law (DGCL) allows the certificate of incorporation (COI) of a Delaware corporation to confer upon one or more directors voting powers greater than or less than those of other directors, thus resulting in “disproportionate voting” rights amongst the Directors.
Read more
Read less

News & Press

Read less

Events & Speaking

Moderator
Oct
10
2018

LSX World Congress USA

Convene - One Boston Place l Boston, MA

Read less

Recognition & Awards

  • Best Lawyers in America: Biotechnology and Life Sciences Practice (2021 - 2023, 2026); Corporate Law (2021 – 2026)

  • Recognized by The Legal 500 United States as “a well-known life sciences expert” for Venture Capital and Emerging Companies (2014)

  • Recommended by The Legal 500 United States for Venture Capital and Emerging Companies (2013 – 2018; 2021 – 2022, 2024); Healthcare: Life Sciences (2020 – 2022, 2024)

  • Martindale-Hubbell AV Preeminent

Read less

Lewis J. Geffen

Member Emeritus